<DOC>
	<DOCNO>NCT01339676</DOCNO>
	<brief_summary>This multi-centre , double blind , randomise , placebo control , parallel group , phase 4 pilot study investigate colecalciferol ( vitamin D3 ) add-on treatment subcutaneously administer interferon-beta-1b relapsing-remitting multiple sclerosis patient .</brief_summary>
	<brief_title>Colecalciferol Add-on Treatment Interferon-beta-1b Treatment Multiple Sclerosis ( MS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>age 18 55 year remittingrelapsing multiple sclerosis accord McDonald criterion fulfill reimbursement criterion interferonbeta use interferonbeta1b least one month EDSS ( expand disability statsu scale ) â‰¤ 5 neutralising antibody INFB measure indirect MxA test prepare consider follow protocol use appropriate contraceptive method ( woman childbearing potential ) give informed consent serum calcium &gt; 2.6 mmol/L serum 25 ( OH ) D2 ( kalsidiol ) &gt; 85 nmol/L presence primary hyperparathyroidism ( serum intact PTH , parathyroid hormone ) &gt; 65 ng/L ) pregnancy unwillingness use contraception alcohol drug abuse use glucocorticoid treatment intravenous methylprednisolone treatment relapse current use immunomodulatory therapy interferonbeta1b know allergy cholecalciferol arachis oil ( peanut ) therapy digitalis , calcitonin active vitamin D3 analogues previous 12 month multivitamin contain vitamin D previous two week precede study entry condition predispose hypercalcaemia ( type cancer ) sarcoidosis nephrolithiasis renal insufficiency , serum creatinine 1.5 time normal upper reference limit significant hypertension ( Blood Pressure &lt; 180/110 mmHg ) hyperthyroidism , hypothyroidism year study begin history nephrolithiasis previous five year cardiac insufficiency significant cardiac dysrhythmia unstable advanced ischaemic heart disease suffer major depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Vitamin D</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>MRI</keyword>
	<keyword>Randomised Trial</keyword>
	<keyword>Finland</keyword>
</DOC>